{"id":5475,"date":"2026-01-15T10:00:01","date_gmt":"2026-01-15T07:00:01","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5475"},"modified":"2026-01-15T10:00:03","modified_gmt":"2026-01-15T07:00:03","slug":"agamree-vamorolone-has-been-approved-in-switzerland-by-swissmedic","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/agamree-vamorolone-has-been-approved-in-switzerland-by-swissmedic\/","title":{"rendered":"AGAMREE (Vamorolone) a re\u00e7u l&#039;autorisation de mise sur le march\u00e9 en Suisse de la part de Swissmedic."},"content":{"rendered":"<p class=\"wp-block-paragraph\">Santhera Pharmaceuticals annonce que l&#039;Agence suisse des produits th\u00e9rapeutiques (Swissmedic) a approuv\u00e9 AGAMREE (vamorolone) pour le traitement de la dystrophie musculaire de Duchenne (DMD) chez les patients \u00e2g\u00e9s de quatre ans et plus. <strong>Apprendre encore plus:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/fr\/what-is-agamree-vamorolone-what-is-agamree-used-for\/\" target=\"_blank\" data-type=\"post\" data-id=\"2333\" rel=\"noreferrer noopener\">Qu&#039;est-ce que AGAMERE (Vamorolone)\u00a0?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Dario Eklund, directeur g\u00e9n\u00e9ral de Santhera, a comment\u00e9 : \u201c En tant qu&#039;entreprise fi\u00e8rement bas\u00e9e en Suisse, l&#039;obtention de l&#039;approbation de Swissmedic repr\u00e9sente une r\u00e9alisation importante et marque notre septi\u00e8me approbation de commercialisation mondiale. <strong>Nous pr\u00e9voyons de lancer AGAMREE en Suisse plus tard en 2026, afin de garantir un acc\u00e8s rapide \u00e0 cette th\u00e9rapie importante pour les patients atteints de DMD dans le pays.<\/strong>\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L\u2019approbation d\u2019AGAMREE par Swissmedic \u00e9tait bas\u00e9e sur les donn\u00e9es de l\u2019\u00e9tude pivotale de phase 2b VISION-DMD et sur les r\u00e9sultats d\u2019\u00e9valuation de l\u2019Agence europ\u00e9enne des m\u00e9dicaments. <strong>Suite \u00e0 cette approbation, la soci\u00e9t\u00e9 s&#039;est vu accorder une p\u00e9riode d&#039;exclusivit\u00e9 de 15 ans en vertu du statut de m\u00e9dicament orphelin suisse.<\/strong> Santhera conserve les droits de distribution exclusifs d&#039;AGAMREE en Suisse et pr\u00e9voit un lancement commercial au second semestre 2026, apr\u00e8s la finalisation des proc\u00e9dures nationales de tarification et de remboursement. <strong>En Suisse, plus de 200 personnes sont atteintes de DMD et disposent de peu d&#039;options de traitement.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>En savoir plus<\/strong>:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/fr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Essais cliniques sur la dystrophie musculaire de Duchenne (Liste de toutes les recherches)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Santhera Pharmaceuticals announces that the Swiss Agency for Therapeutic Products (Swissmedic), has approved AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Learn More: What is AGAMREE (Vamorolone)? Dario Eklund, Chief Executive Officer of Santhera, commented: \u201cAs a proudly Switzerland-based business, securing Swissmedic approval represents an [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5477,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[42,41,477,476,43],"class_list":["post-5475","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-agamree","tag-santhera","tag-swissmedic","tag-switzerland","tag-vamorolone"],"subtitle":"AGAMREE (Vamorolone) devrait \u00eatre lanc\u00e9 en Suisse fin 2026.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/5475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=5475"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/5475\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/5477"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=5475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=5475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=5475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}